Dr. Carini has successfully implemented translational research strategies to reduce the time and costs associated with clinical development while developing drugs at Pfizer Inc., Hoffman La Roche, Novartis and Wyeth. Dr. Carini has also served as faculty at the Johns Hopkins School of Medicine and Harvard University. Dr. Carini has led several strategic, business development committees, and led due diligences for in licensing opportunities. He is board certified in Internal Medicine, Pathology, Respiratory Medicine, and Clinical Immunology.

Dr. Carini is an expert in translational medicine, biomarkers and precision medicine, immunology. He has contributed to biomarkers identification and the success of several projects at the different phases of R&D. Some of those projects led to products market approval.

• University College of London (UCL)
• Royal College of Pathologists

• Translational models
• Biomarkers
• Epigenetics
• Genomics
• Pharmacogenomics
• Proteomics
• Clinical assays
• Human bio-bank

• F-NIH Biomarkers Consortium Cancer, Inflammation & Immunity, Neuroscience Steering Committees
• F-NIH Biomarkers Consortium “ Rheumatoid Arthritis Working Group Steering Committee
• F-NIH Biomarkers Consortium “SLE Working Group” Steering Committee
• F-NIH Biomarkers Consortium “Ankylosing Spondylitis Working Group” Steering Committee
• MRC, UK “MRC/ABPI RA-MAP Consortium – Steering Committee
• MRC, UK “Precision Medicine Consortium” Steering Committee
• IMI, ABIRISK, European Union/EFPIA” Steering Committee
• The PML Consortium, Board of Directors
• The ISAC “Immuno-Safety Advisory Council, Pfizer Board of Directors
• The Generation Scotland Precision Medicine Initiative University of Scotland (UK), Member
• The Immunogenicity Council, Pfizer Board of Directors
• The Grand Challenge Inflammation & Precision Medicine, Univ. of Glasgow
• Biomarkers Development Center, Amsterdam, NL, Advisory Board
• The Kidney Biomarkers Initiative, Pfizer Board of Directors

Dr. Carini has over 200 publications in national and international peer reviewed journals. He has spoken in many venues in several national and international biomarkers conferences, and has been the recipient of meritorious scientific research awards and fellowships. Member of New York Academy of Sciences and of several national and international societies and ad-hoc reviewer for several peer reviewed journals.

Books:

Order Handbook of Biomarkers and Precision Medicine

Order Biomarkers in Drug Development

Order Clinical and Statistical Considerations in Personalized Medicine

• “Biomarkers in Drug Development: A Handbook of Practice, 
Application and Strategy” by J Wiley & Sons, 2010; “Highly commended” for the British Medical Association Medical Book Awards in 2010
• “Clinical Considerations in Statistical and Personalized Medicine, 2014
•  “Handbook of Biomarkers and Precision Medicine”, CRC 2018 in press